Zacks Research Has Optimistic Outlook of DNLI Q2 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Zacks Research raised their Q2 2025 EPS estimates for Denali Therapeutics in a report released on Tuesday, May 27th. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their previous forecast of ($0.85). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($3.14) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($3.18) EPS, Q1 2027 earnings at ($0.74) EPS and FY2027 earnings at ($2.86) EPS.

Other research analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 target price on the stock. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. B. Riley reiterated a "buy" rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Robert W. Baird dropped their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Finally, Bank of America dropped their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $33.71.

Denali Therapeutics Stock Down 2.7%

Denali Therapeutics stock traded down $0.36 during midday trading on Friday, hitting $13.18. 1,205,593 shares of the stock were exchanged, compared to its average volume of 1,110,292. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $33.33. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -4.78 and a beta of 1.49. The business's 50-day moving average price is $13.84 and its 200-day moving average price is $18.52.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the prior year, the company earned ($0.68) EPS.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC grew its holdings in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Denali Therapeutics during the 1st quarter valued at $41,000. GF Fund Management CO. LTD. bought a new position in shares of Denali Therapeutics during the 4th quarter valued at $62,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Denali Therapeutics during the 4th quarter valued at $65,000. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.